Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial

JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304.

Authors

Amanda J Redig¹, Daniel B Costa², Myriam Taibi¹, David Boucher¹, Bruce E Johnson¹, Pasi A Jänne¹, David M Jackman¹

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

PMID: 27387964
DOI: 10.1001/jamaoncol.2016.1304

No abstract available

Publication types

Clinical Trial, Phase II

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Biopsy / methods*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Carcinoma, Non-Small-Cell Lung / pathology
Disease Progression
Drug Resistance, Neoplasm / genetics*
ErbB Receptors / genetics*
Erlotinib Hydrochloride / therapeutic use
Feasibility Studies
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Lung Neoplasms / pathology
Male
Middle Aged
Molecular Targeted Therapy
Prospective Studies
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins c-met / metabolism

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors
MET protein, human
Proto-Oncogene Proteins c-met